Insight, China's Pharmaceutical Industry

Lynk Pharmaceuticals Advances Pan-JAK Inhibitor LNK01004 into Phase II for Vitiligo and Hand Eczema with Skin-Restricted Design

Lynk Pharmaceuticals Co., Ltd. announced that China’s National Medical Products Administration (NMPA) has granted clearance...

Company Drug

CF PharmTech’s Inhaled siRNA Therapy ICF004 Receives NMPA Clinical Approval for Interstitial Lung Disease

Fineline Cube Jun 1, 2026

CF PharmTech Inc. (HKG: 2652) announced that China’s National Medical Products Administration (NMPA) has granted...

Company Deals

Peijia Medical Secures Exclusive China Distribution Rights for B. Braun’s SeQuent Please CIS Intracranial Drug-Coated Balloon

Fineline Cube Jun 1, 2026

Peijia Medical Ltd. (HKG: 9996) announced an exclusive distribution agreement with B. Braun Melsungen AG...

Company Medical Device

Basecare Medical Secures NMPA Category III Approval for Gems Oocyte Retrieval Solution in China’s IVF Market

Fineline Cube Jun 1, 2026

Basecare Medical Device Co., Ltd. (HKG: 2170), a specialist in high-throughput sequencing-based assisted reproduction technologies,...

Company Drug

Shandong Boan Submits Dual Denosumab Biosimilar BLAs to FDA for Osteoporosis and Oncology Indications

Fineline Cube Jun 1, 2026

Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced the submission of Biologics License Applications (BLAs)...

Company Deals

Hanmi Pharm Secures $1.26 Billion Deal with Eli Lilly for GLP-2 Analog Sonefpeglutide in Global Licensing Agreement

Fineline Cube Jun 1, 2026

Hanmi Pharm. Co., Ltd. (“Hanmi”) announced a strategic global licensing agreement with Eli Lilly (NYSE:...

Company Drug

Henlius Biotech’s Perjeta Biosimilar HLX11 (Poherdy) Secures NMPA Approval for HER2-Positive Breast Cancer in China

Fineline Cube Jun 1, 2026

Shanghai Henlius Biotech Inc. (HKG: 2696) announced that the National Medical Products Administration (NMPA) has...

Company Deals

True Health Medical Files Hong Kong IPO for Percutaneous Surgery Robot Portfolio with Multiple China-First Innovations

Fineline Cube Jun 1, 2026

Guangdong True Health Medical Technology Development Co., Ltd., a leading Chinese developer of percutaneous puncture...

Company Drug

Chengdu Kanghua Initiates Phase II Trial for RSV mRNA Vaccine Through NanoRibo Acquisition in China’s Untapped Market

Fineline Cube Jun 1, 2026

Chengdu Kanghua Biological Products Co., Ltd. (SHE: 300841) announced the initiation of a Phase II...

Company Drug

AbbVie’s VENCLYXTO Receives European Commission Approval for Two Novel Fixed-Duration Combinations in First-Line CLL Treatment

Fineline Cube Jun 1, 2026

AbbVie (NYSE: ABBV) announced that the European Commission (EC) has granted an expanded marketing authorization...

Company Drug

Beijing Wantai’s 9-Valent HPV Vaccine Achieves Nationwide Distribution Across 13,000 Vaccination Sites in China

Fineline Cube Jun 1, 2026

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHA: 603392) announced the nationwide commercial launch of...

Company Drug

Bristol-Myers Squibb’s Mezigdomide-Kd Combination Shows 52% Risk Reduction in Relapsed Multiple Myeloma in Phase 3 SUCCESSOR-2 Trial

Fineline Cube Jun 1, 2026

Bristol-Myers Squibb (BMS; NYSE: BMY) announced positive late-breaking results from the Phase 3 SUCCESSOR-2 trial...

Company Drug

AstraZeneca’s IMFINZI-BCG Combination Approved for High-Risk Non-Muscle-Invasive Bladder Cancer in US

Fineline Cube Jun 1, 2026

AstraZeneca (NYSE: AZN) announced that the U.S. Food and Drug Administration (FDA) has approved IMFINZI...

Company Drug

Merck’s Calderasib-Pembrolizumab Combination Receives FDA Breakthrough Therapy Designation for First-Line KRAS G12C-Mutant NSCLC

Fineline Cube Jun 1, 2026

Merck & Co., Inc. (MSD; NYSE: MRK) announced that the U.S. Food and Drug Administration...

Company Drug

Eli Lilly’s Retevmo Shows 83% Risk Reduction in Disease Recurrence for Early-Stage RET Fusion-Positive NSCLC in Phase 3 LIBRETTO-432 Trial

Fineline Cube Jun 1, 2026

Eli Lilly and Company (NYSE: LLY) announced groundbreaking results from the Phase 3 LIBRETTO-432 clinical...

Policy / Regulatory

NMPA Opens 2026 National Reimbursement Drug List Application Window with Revised Eligibility Criteria and Price Controls

Fineline Cube Jun 1, 2026

China’s National Medical Products Administration (NMPA) has released the “2026 Adjustment Work Plan for the...

Company Drug

Teligene’s TL118 Enters NMPA’s SPARK Initiative for Pediatric Cancer Treatment Development

Fineline Cube Jun 1, 2026

The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has included...

Company Drug Policy / Regulatory

FDA Proposes Streamlined Animal Testing Requirements for Oncology Drugs to Accelerate Development Timeline

Fineline Cube Jun 1, 2026

The U.S. Food and Drug Administration (FDA) released draft guidance aimed at reducing unnecessary animal...

Company Drug

Sanofi’s Venglustat Receives FDA Priority Review and Breakthrough Therapy Designation for Type 3 Gaucher Disease

Fineline Cube May 29, 2026

Sanofi (NASDAQ: SNY) announced that the U.S. Food and Drug Administration (FDA) has granted priority...

Company Drug

BeOne Medicines and Amgen’s Tarlatamab Receives NMPA Conditional Approval for Second-Line ES-SCLC in China

Fineline Cube May 29, 2026

BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), formerly BeiGene, announced it has received...

Insight, China's Pharmaceutical Industry

Transcenta and WuXi Biologics Forge Strategic CDMO Partnership with RMB 190 Million Manufacturing Facility Transaction

Biogen Completes $1 Billion Acquisition of RayThera to Bolster Immunology Portfolio with Novel Small-Molecule Pipeline

Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China

AstraZeneca and CSPC Pharmaceutical Establish Joint Venture for Next-Generation Biologics Manufacturing Base in Shijiazhuang

Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance

CARsgen Therapeutics Secures NMPA Clinical Trial Approval for Allogeneic CAR-T Therapy CT1190B in Relapsed/Refractory Large B-Cell Lymphoma

Takeda Expands Revestive Approval in China with New 1.25 mg Specification for Pediatric Short Bowel Syndrome Patients as Young as 4 Months

Lynk Pharmaceuticals Advances Pan-JAK Inhibitor LNK01004 into Phase II for Vitiligo and Hand Eczema with Skin-Restricted Design

CF PharmTech’s Inhaled siRNA Therapy ICF004 Receives NMPA Clinical Approval for Interstitial Lung Disease

Peijia Medical Secures Exclusive China Distribution Rights for B. Braun’s SeQuent Please CIS Intracranial Drug-Coated Balloon

Basecare Medical Secures NMPA Category III Approval for Gems Oocyte Retrieval Solution in China’s IVF Market

Shandong Boan Submits Dual Denosumab Biosimilar BLAs to FDA for Osteoporosis and Oncology Indications

Hanmi Pharm Secures $1.26 Billion Deal with Eli Lilly for GLP-2 Analog Sonefpeglutide in Global Licensing Agreement

Henlius Biotech’s Perjeta Biosimilar HLX11 (Poherdy) Secures NMPA Approval for HER2-Positive Breast Cancer in China

True Health Medical Files Hong Kong IPO for Percutaneous Surgery Robot Portfolio with Multiple China-First Innovations

Chengdu Kanghua Initiates Phase II Trial for RSV mRNA Vaccine Through NanoRibo Acquisition in China’s Untapped Market

AbbVie’s VENCLYXTO Receives European Commission Approval for Two Novel Fixed-Duration Combinations in First-Line CLL Treatment

Beijing Wantai’s 9-Valent HPV Vaccine Achieves Nationwide Distribution Across 13,000 Vaccination Sites in China

Bristol-Myers Squibb’s Mezigdomide-Kd Combination Shows 52% Risk Reduction in Relapsed Multiple Myeloma in Phase 3 SUCCESSOR-2 Trial

AstraZeneca’s IMFINZI-BCG Combination Approved for High-Risk Non-Muscle-Invasive Bladder Cancer in US

Merck’s Calderasib-Pembrolizumab Combination Receives FDA Breakthrough Therapy Designation for First-Line KRAS G12C-Mutant NSCLC

Eli Lilly’s Retevmo Shows 83% Risk Reduction in Disease Recurrence for Early-Stage RET Fusion-Positive NSCLC in Phase 3 LIBRETTO-432 Trial

NMPA Opens 2026 National Reimbursement Drug List Application Window with Revised Eligibility Criteria and Price Controls

Teligene’s TL118 Enters NMPA’s SPARK Initiative for Pediatric Cancer Treatment Development

FDA Proposes Streamlined Animal Testing Requirements for Oncology Drugs to Accelerate Development Timeline

Sanofi’s Venglustat Receives FDA Priority Review and Breakthrough Therapy Designation for Type 3 Gaucher Disease

BeOne Medicines and Amgen’s Tarlatamab Receives NMPA Conditional Approval for Second-Line ES-SCLC in China

You Missed

CARsgen Therapeutics Secures NMPA Clinical Trial Approval for Allogeneic CAR-T Therapy CT1190B in Relapsed/Refractory Large B-Cell Lymphoma

Transcenta and WuXi Biologics Forge Strategic CDMO Partnership with RMB 190 Million Manufacturing Facility Transaction

Takeda Expands Revestive Approval in China with New 1.25 mg Specification for Pediatric Short Bowel Syndrome Patients as Young as 4 Months

Hengrui Pharmaceuticals Secures Fifth NMPA Approval for Ivarmacitinib in Non-Radiographic Axial Spondyloarthritis